… of new treatment options for Crohn's disease (CD) and ulcerative colitis (UC). … vedolizumab
and ustekinumab. They have different therapeutic targets (α 4 β 7 integrin for vedolizumab …

… diseases affecting the gastrointestinal tract. The use of anti-tumour necrosis factor [… inflammatory
pathways have been approved for IBD in recent years: vedolizumab 3 and ustekinumab. …

… data of vedolizumab and ustekinumab, … ustekinumab and vedolizumab in achieving clinical
remission in anti-TNF-experienced CD.70-72 The efficacy of ustekinumab and vedolizumab …

… ongoing evidence of inflammation five months post initiation of ustekinumab; so vedolizumab
was added. Five months after adding vedolizumab to ustekinumab abdominal pain and …

… found between vedolizumab and ustekinumab regarding their … Another recent study found
patients treated with vedolizumab … in vedolizumab versus ustekinumab therapy IBD patients. …

… We performed a retrospective study of patients with CD or UC initiating vedolizumab or
ustekinumab therapy at Massachusetts General Hospital (USA), Alberta Health Sciences (…

… We report 73 pregnancies in patients receiving vedolizumab or ustekinumab without a
negative signal on maternal or neonatal outcomes. Further prospective studies are needed on the …

… by the European Crohn’s and Colitis Organisation [ECCO] and … lesions associated with
inflammatory bowel disease [IBD] … newer biologic agents ustekinumab [UST] or vedolizumab [VDZ…

… , ustekinumab and vedolizumab, where data is limited. We hypothesized that ustekinumab-…
a similar overall postoperative complication rate as vedolizumab-treated patients. The aim …

… treatment of moderate and severely active inflammatory bowel disease (IBD), because they
… target different inflammatory pathways in Crohn’s disease (CD) and ulcerative colitis (UC) …